Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 17,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elevate Clear all
Completed Phase 4 Interventional Results available

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

NCT00145574
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl, placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • New Hyde Park, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

NCT01666782
View directory record Official record
Conditions
Cancer, Influenza Viral Infections
Interventions
Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine
Biological
Lead sponsor
Saad Jamshed MD
Other
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women

NCT01364623
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
Low dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, single dose, High dose testosterone nasal gel, single dose, Medium dose testosterone nasal gel, multiple dose
Drug
Lead sponsor
Acerus Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Terminated Phase 1 Interventional

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

NCT00757250
View directory record Official record
Conditions
HIV Infections
Interventions
Angiotensin 1-7
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113
View directory record Official record
Conditions
Neurocognitive Improvement
Interventions
Citicoline, Microcrystalline Cellulose
Drug · Other
Lead sponsor
Deborah Yurgelun-Todd
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair

NCT03208920
View directory record Official record
Conditions
PAD, Abdominal Aortic Aneurysm
Interventions
Pro-Omega, ProOmega Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 30, 2026, 4:25 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

NCT04896320
View directory record Official record
Conditions
Breast Cancer Stage IV
Interventions
Tucatinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Clackamas, Oregon • Newberg, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Not listed Phase 1 Interventional

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

NCT00022880
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Iodine-131 Anti-B1 Antibody
Drug
Lead sponsor
Corixa Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Palo Alto, California • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

NCT06122896
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasm
Interventions
Screening Blood Tests, Endoscopic Ultrasound, Magnetic Resonance Imaging, Magnetic Resonance Cholangiopancreatography
Other · Diagnostic Test · Combination Product
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2041
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Results available

Accelerating Word Learning in Children With Language Impairment

NCT01829360
View directory record Official record
Conditions
Specific Language Impairment
Interventions
Treatment (interactive book reading, dialogic reading, shared book reading)
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
5 Years to 6 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 30, 2026, 4:25 PM EDT
Not listed Not applicable Interventional

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients

NCT00459160
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma, Wounds, Penetrating, Shock, Traumatic, Multiple Trauma
Interventions
Intraoperative Hypotensive Resuscitation
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Maintenance Lenalidomide in Lymphoma

NCT01575860
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

NCT06040320
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disorder
Interventions
Polatuzumab vedotin, Rituximab, CHP
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

NCT01926782
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Statin
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 30, 2026, 4:25 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Cholecalciferol and Flu Vaccine in Treating Healthy Participants

NCT01561989
View directory record Official record
Conditions
Healthy, no Evidence of Disease
Interventions
cholecalciferol, questionnaire administration, trivalent influenza vaccine
Dietary Supplement · Other · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 30, 2026, 4:25 PM EDT
Not yet recruiting Not applicable Interventional

Antibiotic-coated Braided Suture Study

NCT07322289
View directory record Official record
Conditions
Prosthetic Joint Infection, Debridement With Prosthesis Retention, Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Suture
Interventions
VICRYL™ Plus (Coated VICRYL™ Plus Antibacterial), Polydioxanone (PDS™ II ) Sterile Synthetic Absorbable Surgical Suture-Monofilament
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 89 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274
View directory record Official record
Conditions
Bioequivalence
Interventions
Tacrolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

NCT04964518
View directory record Official record
Conditions
AML, Adult
Interventions
APG 2575 ramp up arm
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)

NCT02091882
View directory record Official record
Conditions
Device Latency
Interventions
Placebo, Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Drug · Combination Product
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 30, 2026, 4:25 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Hearing Aid Algorithms for Sudden Sounds

NCT06340919
View directory record Official record
Conditions
Hearing Loss
Interventions
Sudden Sound Reduction Setting
Device
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 4:25 PM EDT
Recruiting Phase 2 Interventional

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

NCT06949800
View directory record Official record
Conditions
HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions
EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Communities Fighting COVID-19!

NCT05148936
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 Testing Home-based (Aim 1), COVID-19 Testing Mobile (Aim 1), COVID-19 Testing Mobile Approach 1 (Aim 2), COVID-19 Testing Mobile Approach 2 (Aim 2)
Other
Lead sponsor
San Diego State University
Other
Eligibility
6 Years to 120 Years
Enrollment
32,750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 30, 2026, 4:25 PM EDT
Not listed No phase listed Observational

Cardiovascular Manifestations of COVID-19

NCT04335630
View directory record Official record
Conditions
Cardiovascular Diseases, COVID
Interventions
Electrocardiogram, telemetry, echocardiogram, laboratory values
Diagnostic Test
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 30, 2026, 4:25 PM EDT
Active, not recruiting Not applicable Interventional

Assessing Feasibility of Prolonged Repetitive Near Infrared Light Stimulation in Early to Mid-Stage Dementia

NCT03750409
View directory record Official record
Conditions
Mild to Moderate Dementia
Interventions
Helmet
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
50 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Elkins Park, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 30, 2026, 4:25 PM EDT